NCT04562129View on ClinicalTrials.gov

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

November 30, 2029

Conditions
Melanoma Stage IIIMelanoma Stage IVInoperable Disease
Interventions
DRUG

Interleukin-2

High dose interleukin-2 (HD IL2) administered week 1 and 4 of each course (approximately 12 weeks)

DRUG

Ipilimumab

Low dose Ipilimumab given at time of HD IL2 administration on day 1 of the first 2 cycles of each course.

DRUG

Nivolumab

Nivolumab will be given at a dose of 480 mg IV week 7 of each course.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

Clinigen, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER